Natural Psilocybin2024-05-15T11:29:12+02:00

Informed by nature
and guided by science

Informed
by nature

and guided
by science

Pioneering the use of natural psychedelics for mental health

We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.

Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.

Our key focus area is palliative care. and associated ailments, within the context of palliative care. In particular, Psyence is targeting the indications of anxiety and depression,

We develop natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment. Psyence Therapeutics is now housed in the NASDAQ listed entity Psyence Biomedical Ltd (NASDAQ:PBM).

We operate one of the first federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world.

Our range of functional mushroom wellness products harness the power of adaptogens – non-toxic, non-psychoactive fungi used in ancient medicine for their stress relieving and general wellness benefits.

Bringing together leaders in the business of medicine and science
Our Team Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth
Psyence Production - Psilocybin

Bringing together leaders in the business of medicine and science

Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.

Our News

Our Global Footprint

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and quoted on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions.

Our Global Footprint

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and quoted on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions.

Our News

  • PYSENCE_FEATURE_29

Psyence Group Inc. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

June 27, 2025|

Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of the Offering will be used for general working capital purposes.

Psyence Group Inc. Announces Offering of up C$600,000 Non-Brokered Private Placement of Common Shares

June 19, 2025|

Psyence Group Inc are pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000.  No finder’s fees or commissions will be payable in connection with the Offering.

Psyence Group Announces Share Consolidation

June 5, 2025|

Psyence Group Inc announces that the Company will be consolidating all of its issued and outstanding share capital (the “Common Shares”) on the basis of every fifteen (15) old Common Shares into one (1) new Common Share (the “Share Consolidation”), effective April 23, 2025 with a record date of April 23, 2025 (the “Record Date”).

Go to Top